Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22365183 | 0.86 | CYP1A2 (0.36) | KMT2ABCHEACHEMEN1 | |
| SCHEMBL20144614 | 0.85 | EPHX2 (0.38) | KMT2AHDAC8EPHX2 | |
| SCHEMBL1887808 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL20450544 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL1677088 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL24819248 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL20144613 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL20467657 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL20467680 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 | |
| SCHEMBL26413508 | 0.84 | KMT2A (0.44) | KMT2APOLBHDAC8EPHX2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179467-B2 | Exenatide modifier and use thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179467-B2 | Exenatide modifier and use thereof | GLP1R, GCGR, GIPR | KMT2A 3214/4885POLB 4799/4885HDAC8 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.